The role of epidermal growth factor receptor in cancer metastasis and microenvironment

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Sasaki, Takamitsu ^a   Hiroki, Kuniyasu ^b   Yamashita, Yuichi ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GEFITINIB; GELATINASE A; GELATINASE B; INTERLEUKIN 8; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

APOPTOSIS; BILIARY TRACT CANCER; BRAIN METASTASIS; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CELL ACTIVATION; CELL INTERACTION; CELL SPREADING; COLON CANCER; COLON METASTASIS; COLORECTAL CANCER; ENDOTHELIUM CELL; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; HOST CELL; HUMAN; METASTASIS; METASTATIC COLORECTAL CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; METABOLISM; NEOPLASM; PATHOLOGY; NEOPLASMS;

ANIMALS; EPIDERMAL GROWTH FACTOR; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84883155020     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/546318     Document Type: Review

References (79)

1. Normanno N., de Luca A., Bianco C., Strizzi L., Mancino M., Maiello M. R., Carotenuto A., de Feo G., Caponigro F., Salomon D. S., Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006 366 1 2 16 2-s2.0-32044464123 10.1016/j.gene.2005.10.018
2. Carpenter G., Cohen S., Epidermal growth factor. The Journal of Biological Chemistry 1990 265 14 7709 7712 2-s2.0-0025321157
3. Alroy I., Yarden Y., The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Letters 1997 410 1 83 86 2-s2.0-0030795612 10.1016/S0014-5793(97)00412-2
4. Hynes N. E., Lane H. A., ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer 2005 5 5 341 354 2-s2.0-18344390418 10.1038/nrc1609
5. Mendelsohn J., Baselga J., The EGF receptor family as targets for cancer therapy. Oncogene 2000 19 56 6550 6565 2-s2.0-0034722889 10.1038/sj.onc.1204082
6. Wong A. J., Ruppert J. M., Bigner S. H., Grzeschik C. H., Humphrey P. A., Bigner D. S., Vogelstein B., Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proceedings of the National Academy of Sciences of the United States of America 1992 89 7 2965 2969 2-s2.0-0026548240
7. Umekita Y., Ohi Y., Sagara Y., Yoshida H., Co-expression of epidermal growth factor receptor and transforming growth factor- α predicts worse prognosis in breast cancer patients. International Journal of Cancer 2000 89 6 484 487 10.1002/1097-0215(20001120)89:6<484::AID-IJC3>3.0.CO;2-S
8. Uhlman D. L., Nguen P., Manivel J. C., Zhang G., Hagen K., Fraley E., Aeppli D., Niehans G. A., Epidermal growth factor receptor and transforming growth factor α expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. Clinical Cancer Research 1995 1 8 913 920 2-s2.0-0029146750
9. Swinson D. E. B., Cox G., O'Byrne K. J., Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer. The British Journal of Cancer 2004 91 7 1301 1307 2-s2.0-6944233742 10.1038/sj.bjc.6602149
10. Grandis J. R., Melhem M. F., Gooding W. E., Day R., Holst V. A., Wagener M. M., Drenning S. D., Tweardy D. J., Levels of TGF- α and EGFR protein in head and neck squamous cell carcinoma and patient survival. Journal of the National Cancer Institute 1998 90 11 824 832 2-s2.0-0032478998
11. Carraway K. L. III, Cantley L. C., A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 1994 78 1 5 8 2-s2.0-0028176477 10.1016/0092-8674(94)90564-9
12. van der Geer P., Hunter T., Lindberg R. A., Receptor protein-tyrosine kinases and their signal transduction pathways. Annual Review of Cell Biology 1994 10 251 337 2-s2.0-0028170817
13. Ullrich A., Coussens L., Hayflick J. S., Dull T. J., Gray A., Tam A. W., Lee J., Yarden Y., Libermann T. A., Schlessinger J., Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984 309 5967 418 425 2-s2.0-0021273420
14. Carpenter G., King L. Jr., Cohen S., Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro. Nature 1978 276 5686 409 410 2-s2.0-0018236378
15. Ushiro H., Cohen S., Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. The Journal of Biological Chemistry 1980 255 18 8363 8365 2-s2.0-0019332971
16. Groenen L. C., Nice E. C., Burgess A. W., Structure-function relationships for the EGF/TGF- α family of mitogens. Growth Factors 1994 11 4 235 257 2-s2.0-0028618937
17. Toyoda H., Komurasaki T., Uchida D., Takayama Y., Isobe T., Okuyama T., Hanada K., Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. The Journal of Biological Chemistry 1995 270 13 7495 7500 2-s2.0-0028937620 10.1074/jbc.270.13.7495
18. Chen W. S., Lazar C. S., Poenie M., Tsien R. Y., Gill G. N., Rosenfeld M. G., Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor. Nature 1987 328 6133 820 823 2-s2.0-0023238874
19. Perugini R. A., McDade T. P., Vittimberga F. J. Jr., Callery M. P., Pancreatic cancer cell proliferation phosphatidylinositol 3-kinase dependent. Journal of Surgical Research 2000 90 1 39 44 2-s2.0-0034194348 10.1006/jsre.2000.5833
20. Nicholson K. M., Anderson N. G., The protein kinase B/Akt signalling pathway in human malignancy. Cellular Signalling 2002 14 5 381 395 2-s2.0-0036185848 10.1016/S0898-6568(01)00271-6
21. Wang W., Abbruzzese J. L., Evans D. B., Larry L., Cleary K. R., Chiao P. J., The nuclear factor- B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clinical Cancer Research 1999 5 1 119 127 2-s2.0-0032943591
22. Douziech N., Calvo E., Laine J., Morisset J., Activation of MAP kinases in growth responsive pancreatic cancer cells. Cellular Signalling 1999 11 8 591 602 2-s2.0-0032988428 10.1016/S0898-6568(99)00030-3
23. Yokoi K., Thaker P. H., Yazici S., Rebhun R. R., Nam D., He J., Kim S., Abbruzzese J. L., Hamilton S. R., Fidler I. J., Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Research 2005 65 9 3716 3725 2-s2.0-20944433324 10.1158/0008-5472.CAN-04-3700
24. Shaheen R. M., Ahmad S. A., Liu W., Reinmuth N., Jung Y. D., Tseng W. W., Drazan K. E., Bucana C. D., Hicklin D. J., Ellis L. M., Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. The British Journal of Cancer 2001 85 4 584 589 2-s2.0-17944370631 10.1054/bjoc.2001.1936
25. Saltz L. B., Meropol N. J., Loehrer P. J. Sr., Needle M. N., Kopit J., Mayer R. J., Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. Journal of Clinical Oncology 2004 22 7 1201 1208 2-s2.0-2142641698 10.1200/JCO.2004.10.182
26. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., Chau I., van Cutsem E., Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England Journal of Medicine 2004 351 4 337 345 2-s2.0-3242720345 10.1056/NEJMoa033025
27. de Jong K. P., Slellema R., Karrenbeld A., Koudstaal J., Gouw A. S. H., Sluiter W. J., Peeters P. M. J. G., Slooff M. J. H., De Vries E. G. E., Clinical relevance of transforming growth factor α epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology 1998 28 4 I 971 979 2-s2.0-0031708626 10.1002/hep.510280411
28. Toschi L., Cappuzzo F., Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 2007 12 2 211 220 2-s2.0-33847068819 10.1634/theoncologist.12-2-211
29. Veale D., Kerr N., Gibson G. J., Kelly P. J., Harris A. L., The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. The British Journal of Cancer 1993 68 1 162 165 2-s2.0-0027232422
30. Rajput A., Koterba A. P., Kreisberg J. L., Foster J. M., Willson J. K. V., Brattain M. G., A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. Cancer Research 2007 67 2 665 673 2-s2.0-33846696437 10.1158/0008-5472.CAN-06-2773
31. Janmaat M. L., Giaccone G., The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs of Today 2003 39 61 80 2-s2.0-0345098554 10.1358/dot.2003.39.1.799432
32. Mendelsohn J., The epidermal growth factor receptor as a target for cancer therapy. Endocrine-Related Cancer 2001 8 1 3 9 2-s2.0-0034988184 10.1677/erc.0.0080003
33. Herbst R. S., Review of epidermal growth factor receptor biology. International Journal of Radiation Oncology Biology Physics 2004 59 2 21 26 2-s2.0-2342492317 10.1016/j.ijrobp.2003.11.041
34. Herbst R. S., Review of epidermal growth factor receptor biology. International Journal of Radiation Oncology Biology Physics 2004 59 2 21 26 2-s2.0-2342492317 10.1016/j.ijrobp.2003.11.041
35. Radinsky R., Risin S., Fan D., Dong Z., Bielenberg D., Bucana C. D., Fidler I. J., Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clinical Cancer Research 1995 1 1 19 31 2-s2.0-0028960781
36. Barozzi C., Ravaioli M., D'Errico A., Grazi G. L., Poggioli G., Cavrini G., Mazziotti A., Grigioni W. F., Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel. Cancer 2002 94 3 647 657 2-s2.0-0036469151 10.1002/cncr.10278
37. Hemming A. W., Davis N. L., Kluftinger A., Robinson B., Quenville N. F., Liseman B., LeRiche J., Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. Journal of Surgical Oncology 1992 51 3 147 152 2-s2.0-0026471016 10.1002/jso.2930510304
38. Resnick M. B., Routhier J., Konkin T., Sabo E., Pricolo V. E., Epidermal growth factor receptor, c-MET, β -catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clinical Cancer Research 2004 10 9 3069 3075 2-s2.0-2442480522 10.1158/1078-0432.CCR-03-0462
39. Harris A. L., Hypoxia-a key regulatory factor in tumour growth. Nature Reviews Cancer 2002 2 1 38 47 2-s2.0-0036359548
40. Suhardja A., Hoffman H., Role of growth factors and their receptors in proliferation of microvascular endothelial cells. Microscopy Research and Technique 2003 60 1 70 75 2-s2.0-0037221174 10.1002/jemt.10245
41. Ellis L. M., Liu W., Ahmad S. A., Fan F., Jung Y. D., Shaheen R. M., Reinmuth N., Overview of angiogenesis: biologic implicat ions for antiangiogenic therapy. Seminars in Oncology 2001 28 5, supplement 16 94 104 10.1016/S0093-7754(01)90287-8
42. Langley R. R., Fidler I. J., Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocrine Reviews 2007 28 3 297 321 2-s2.0-34250857019 10.1210/er.2006-0027
43. Gupta G. P., Massagué J., Cancer metastasis: building a framework. Cell 2006 127 4 679 695 2-s2.0-33751252276 10.1016/j.cell.2006.11.001
44. Fidler I. J., Yano S., Zhang R., Fujimaki T., Bucana C. D., The seed and soil hypothesis: vascularisation and brain metastases. The Lancet Oncology 2002 3 1 53 57 2-s2.0-0036161382 10.1016/S1470-2045(01)00622-2
45. Hobson B., Denekamp J., Endothelial proliferation in tumours and normal tissues: continuous labelling studies. The British Journal of Cancer 1984 49 4 405 413 2-s2.0-0021239705
46. Eberhard A., Kahlert S., Goede V., Hemmerlein B., Plate K. H., Augustin H. G., Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Research 2000 60 5 1388 1393 2-s2.0-0034161989
47. Iqbal S., Lenz H., Integration of novel agents in the treatment of colorectal cancer. Cancer Chemotherapy and Pharmacology 2004 54 1 S32 S39 2-s2.0-8744262693 10.1007/s00280-004-0884-0
48. Langley R. R., Fan D., Tsan R. Z., Rebhun R., He J., Kim S., Fidler I. J., Activation of the platelet-derived growth factor-receptor enhances survival of murine bone endothelial cells. Cancer Research 2004 64 11 3727 3730 2-s2.0-2542582262 10.1158/0008-5472.CAN-03-3863
49. Kim S. J., Uehara H., Karashima T., Shepherd D. L., Killion J. J., Fidler I. J., Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clinical Cancer Research 2003 9 3 1200 1210 2-s2.0-0037341379
50. Sasaki T., Nakamura T., Rebhun R. B., Cheng H., Hale K. S., Tsan R. Z., Fidler I. J., Langley R. R., Modification of the primary tumor microenvironment by transforming growth factor α -epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model. The American Journal of Pathology 2008 173 1 205 216 2-s2.0-46749145782 10.2353/ajpath.2008. 071147
51. Ferrara N., Davis-Smyth T., The biology of vascular endothelial growth factor. Endocrine Reviews 1997 18 1 4 25 2-s2.0-0031039243 10.1210/er.18.1.4
52. Dvorak H. F., Brown L. F., Detmar M., Dvorak A. M., Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. The American Journal of Pathology 1995 146 5 1029 1039 2-s2.0-0029004025
53. Mook O. R. F., Frederiks W. M., van Noorden C. J. F., The role of gelatinases in colorectal cancer progression and metastasis. Biochimica et Biophysica Acta 2004 1705 2 69 89 2-s2.0-9944258056 10.1016/j.bbcan.2004.09.006
54. Schoppmann S. F., Birner P., Stöckl J., Kalt R., Ullrich R., Caucig C., Kriehuber E., Nagy K., Alitalo K., Kerjaschki D., Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. The American Journal of Pathology 2002 161 3 947 956 2-s2.0-0036733564
55. Maruyama K., Asai J., Ii M., Thorne T., Losordo D. W., D'Amore P. A., Decreased macrophage number and activation lead to reduced lymphatic vessel formation and contribute to impaired diabetic wound healing. The American Journal of Pathology 2007 170 4 1178 1191 2-s2.0-34247874642 10.2353/ajpath.2007.060018
56. Sasaki T., Kitadai Y., Nakamura T., Kim J., Tsan R. Z., Kuwai T., Langley R. R., Fan D., Kim S., Fidler I. J., Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice. Neoplasia 2007 9 12 1066 1077 2-s2.0-37149040461 10.1593/neo.07667
57. Saito N., Kameoka S., Furukawa R., Gene profile analysis of colorectal cancer cell lines by cDNA macroarray. Oncology reports 2007 17 5 1061 1065 2-s2.0-34548562029
58. Liotta L. A., Kleinerman J., Saidel G. M., Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Research 1974 34 5 997 1004 2-s2.0-0016218630
59. Harder J., Waiz O., Otto F., Geissler M., Olschewski M., Weinhold B., Blum H. E., Schmitt-Graeff A., Opitz O. G., EGFR and HER2 expression in advanced biliary tract cancer. World Journal of Gastroenterology 2009 15 36 4511 4517 2-s2.0-71749120396 10.3748/wjg.15.4511
60. Kaufman M., Mehrotra B., Limaye S., White S., Fuchs A., Lebowicz Y., Nissel-Horowitz S., Thomas A., EGFR expression in gallbladder carcinoma in North America. International Journal of Medical Sciences 2008 5 5 285 291 2-s2.0-54749094335
61. Leone F., Cavalloni G., Pignochino Y., Sarotto I., Ferraris R., Piacibello W., Venesio T., Capussotti L., Risio M., Aglietta M., Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clinical Cancer Research 2006 12 6 1680 1685 2-s2.0-33645689431 10.1158/1078-0432.CCR-05-1692
62. Ooi A., Suzuki S., Nakazawa K., Itakura J., Imoto I., Nakamura H., Dobashi Y., Gene amplification of Myc and its coamplification with ERBB2 and EGFR in gallbladder adenocarcinoma. Anticancer Research 2009 29 1 19 26 2-s2.0-61449126478
63. Pignochino Y., Sarotto I., Peraldo-Neia C., Penachioni J. Y., Cavalloni G., Migliardi G., Casorzo L., Chiorino G., Risio M., Bardelli A., Aglietta M., Leone F., Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 2010 10 article 361 2-s2.0-78349300249 10.1186/1471-2407-10-361
64. Sanada Y., Osada S., Tokuyama Y., Tanaka Y., Takahashi T., Yamaguchi K., Yoshida K., Critical role of c-Met and Ki67 in progress of biliary carcinoma. The American Surgeon 2010 76 4 372 379 2-s2.0-77950388953
65. Moon W. S., Park H. S., Lee H., Pai R., Tarnawski A. S., Kim K. R., Jang K. Y., Co-expression of cox-2, C-met and betacatenin in cells forming invasive front of gallbladder cancer. Cancer Research and Treatment 2005 37 3 171 176 10.4143/crt.2005.37.3.171
66. Matsumoto K., Date K., Shimura H., Nakamura T., Acquisition of invasive phenotype in gallbladder cancer cells via mutual interaction of stromal fibroblasts and cancer cells as mediated by hepatocyte growth factor. Japanese Journal of Cancer Research 1996 87 7 702 710 2-s2.0-0029763516
67. Kitamura K., Kasuya K., Tsuchida A., Mimuro A., Inoue K., Aoki T., Aoki T., Koyanagi Y., Immunohistochemical analysis of transforming growth factor beta in gallbladder cancer. Oncology reports 2003 10 2 327 332 2-s2.0-0038148430
68. Yukawa M., Fujimori T., Hirayama D., Idei Y., Ajiki T., Kawai K., Sugiura R., Maeda S., Nagasako K., Expression of oncogene products and growth factors in early gallbladder cancer, advanced gallbladder cancer, and chronic cholecystitis. Human Pathology 1993 24 1 37 40 2-s2.0-0027474581 10.1016/0046-8177(93)90060-T
69. Chang H. Y., Kao M. C., Way T. D., Ho C. T., Fu E., Diosgenin suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition by down-regulation of Mdm2 and vimentin. Journal of Agricultural and Food Chemistry 2011 59 10 5357 5363 2-s2.0-79957940895 10.1021/jf200598w
70. Barr S., Thomson S., Buck E., Russo S., Petti F., Sujka-Kwok I., Eyzaguirre A., Rosenfeld-Franklin M., Gibson N. W., Miglarese M., Epstein D., Iwata K. K., Haley J. D., Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clinical and Experimental Metastasis 2008 25 6 685 693 2-s2.0-47549092230 10.1007/s10585-007-9121-7
71. McConkey D. J., Choi W., Marquis L., Martin F., Williams M. B., Shah J., Svatek R., Das A., Adam L., Kamat A., Siefker-Radtke A., Dinney C., Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer and Metastasis Reviews 2009 28 3-4 335 344 2-s2.0-76649134077 10.1007/s10555-009-9194-7
72. Moustakas A., Heldin C. H., Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Science 2007 98 10 1512 1520 2-s2.0-34548175512 10.1111/j.1349-7006.2007. 00550.x
73. Lee M. Y., Chou C. Y., Tang M. J., Shen M. R., Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation. Clinical Cancer Research 2008 14 15 4743 4750 2-s2.0-51049109014 10.1158/1078-0432.CCR-08-0234
74. Hirata A., Ogawa S., Kometani T., Kuwano T., Naito S., Kuwano M., Ono M., ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Research 2002 62 9 2554 2560 2-s2.0-0036570203
75. Ciardiello F., Bianco R., Damiano V., de Lorenzo S., Pepe S., de Placido S., Fan Z., Mendelsohn J., Bianco A. R., Tortora G., Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clinical Cancer Research 1999 5 4 909 916 2-s2.0-0032904485
76. Erlichman C., Sargent D. J., New treatment options for colorectal cancer. The New England Journal of Medicine 2004 351 4 391 392 2-s2.0-3242703033 10.1056/NEJMe048151
77. Liu B., Fang M., Schmidt M., Lu Y., Mendelsohn J., Fan Z., Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. The British Journal of Cancer 2000 82 12 1991 1999 2-s2.0-0034038282
78. Xu L., Hausmann M., Dietmaier W., Kellermeier S., Pesch T., Stieber-Gunckel M., Lippert E., Klebl F., Rogler G., Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. BMC Cancer 2010 10 article 302 2-s2.0-77953636872 10.1186/1471-2407-10-302
79. Ariyama H., Qin B., Baba E., Tanaka R., Mitsugi K., Harada M., Nakano S., Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. Journal of Cellular Biochemistry 2006 97 4 724 734 2-s2.0-33644998898 10.1002/jcb.20678